Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

关于ELAHERE ELAHERE为中美华东与ImmunoGen, Inc.（目前已被AbbVie收购）合作开发的针对叶酸受体α（FRα，一种在卵巢癌中高表达的细胞表面蛋白）靶点的 ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

SAN DIEGO - 专注于癌症精准治疗的临床阶段生物制药公司Kura Oncology, Inc. (NASDAQ:KURA)今日宣布任命Michael Vasconcelles医学博士加入其董事会。Vasconcelles博士为公司带来了超过25年的肿瘤药物开发经验。 Vasconcelles博士以其在研发和监管事务方面的丰富背景而闻名，曾在多家生物制药公司担任领导职务，包括ImmunoGe ...

The market has climbed 2.6% in the last 7 days and is up 31% over the last 12 months, with earnings forecast to grow by 15% ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.